New pill combo aims to control bile duct cancer when standard care fails
NCT ID NCT07146646
First seen Nov 12, 2025 · Last updated Jun 17, 2026 · Updated 29 times
Summary
This study tests a new combination of two chemotherapy drugs—a pill (trifluridine/tipiracil) plus an IV drug (oxaliplatin)—for people with advanced bile duct or gallbladder cancer whose first treatment stopped working or didn't help. The goal is to see if this combo controls the cancer better than the usual second-line treatment (FOLFOX). About 27 adults will take part, and researchers will measure how many patients' cancer stops growing or shrinks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center
NOT_YET_RECRUITINGCleveland, Ohio, 44195, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
RECRUITINGCleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.